Lupin receives USFDA nod for generic Namenda XR Capsules

Pharma Major Lupin Limited announced that it has received final approval for its Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg from the United States Food and Drug Administration (FDA) to market a generic version of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg.

Lupin's Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg are the AB rated generic equivalent of Allergan’s Namenda XR Capsules, 7 mg, 14 mg, 21 mg, and 28 mg.

Memantine Hydrochloride Extended-Release Capsules, 7 mg, 14 mg, 21 mg, and 28 mg are indicated for treatment of moderate to severe dementia of the Alzheimer's type. Namenda XR Capsules had US sales of USD 1.22 Billion